Hough Christina M, Kruse Jennifer L, Espinoza Randall T, Brooks John O, Congdon Eliza J, Norris Viviane, Craske Michelle G, Narr Katherine L
Department of Psychology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Department of Psychiatry & Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Brain Behav Immun Health. 2024 Dec 15;43:100925. doi: 10.1016/j.bbih.2024.100925. eCollection 2025 Feb.
Electroconvulsive therapy (ECT) is a highly efficacious intervention for severe and intractable depression. Evidence suggests ECT provokes an initial acute inflammatory response that subsequently decreases with repeated administration. However, relationships between inflammatory changes and clinical effects are unclear. Improved understanding of these processes may provide critical insight into effective intervention for treatment-resistant depression (TRD).
Plasma inflammatory markers were assessed at pre-treatment (T1), after the second ECT session (T2), and after ECT index series completion (post-treatment/T3) in TRD (n = 40). Changes were examined over time and in association with post-treatment Responder/Non-responder status (≥50% reduction in global depression severity) and percent change in affective, cognitive and neurovegetative depressive symptom domains.
C-reactive protein (CRP) and interleukin-6 (IL-6) increased from pre-treatment to T2, and decreased from T2 to post-treatment. Neither early (%T2-T1) nor total (%T1-T3) change in inflammation predicted clinical outcomes, however, the interaction between early/acute inflammatory response and post-treatment inflammation (relative to baseline) was associated with clinical outcomes. Larger initial increases in IL-6 predicted greater reductions in both affective and cognitive symptoms in subjects with higher post-treatment IL-6; those with lower post-treatment IL-6 trended toward the opposite. The same was found between changes in CRP and neurovegetative symptoms.
Though preliminary, these results demonstrate how processes involved in the acute inflammatory response to ECT may differentially influence clinical outcomes depending on overall trajectory of inflammation following ECT. Findings also highlight the importance of examining symptom-specific changes in depression when studying treatment mechanisms, rather than relying solely on global measures of severity.
电休克疗法(ECT)是治疗重度难治性抑郁症的一种高效干预措施。有证据表明,ECT会引发初始急性炎症反应,而这种反应会随着重复治疗而减弱。然而,炎症变化与临床疗效之间的关系尚不清楚。深入了解这些过程可能为治疗难治性抑郁症(TRD)的有效干预措施提供关键见解。
对40例TRD患者在治疗前(T1)、第二次ECT治疗后(T2)以及ECT指数疗程结束后(治疗后/T3)评估血浆炎症标志物。观察炎症标志物随时间的变化,并分析其与治疗后反应者/无反应者状态(全球抑郁严重程度降低≥50%)以及情感、认知和神经植物性抑郁症状领域的变化百分比之间的关联。
C反应蛋白(CRP)和白细胞介素-6(IL-6)从治疗前到T2升高,从T2到治疗后降低。炎症的早期变化(%T2 - T1)和总体变化(%T1 - T3)均不能预测临床结果,然而,早期/急性炎症反应与治疗后炎症(相对于基线)之间的相互作用与临床结果相关。治疗后IL-6较高的受试者中,IL-6初始升高幅度越大,情感和认知症状的减轻幅度越大;治疗后IL-6较低的受试者则呈现相反趋势。CRP变化与神经植物性症状之间也有同样的发现。
尽管这些结果是初步的,但它们表明ECT急性炎症反应所涉及的过程可能会根据ECT后炎症的总体轨迹对临床结果产生不同影响。研究结果还强调了在研究治疗机制时检查抑郁症症状特异性变化的重要性,而不是仅仅依赖于严重程度的总体测量。